Search
forLearn
5 / 33 resultslearn Stemoxydine
chemical from L'Oreal that encourages hair to enter growth phase
learn Adenosine
nucleoside used for hair regrowth stimulant properties
learn Exosomes
Microscopic delivery system that sends growth-promoting signals to hair follicles
learn Latanoprost
glaucoma medication with hair follicle stimulant effects
Research
5 / 1000+ resultsresearch A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results
Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
research Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
Setipiprant did not significantly improve hair growth in men with hair loss.
research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Samcyprone (Diphenylcyclopropenone Ointment) for the Treatment of Common Warts
Samcyprone ointment is effective for treating common warts if a sensitization reaction occurs first.
Community Join
5 / 1000+ resultscommunity Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community PP405 Phase 2a press release with early results
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
community Pelage Announces Positive Results of Phase 2a Trials for PP405
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.
community Follicum releases some data from previous phase 2a trial
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.